Precision

Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain

Retrieved on: 
Martedì, Maggio 28, 2024
Patient, Doctor of Philosophy, Electrode, Trial of the century, Sale, MD, Research, Neurosurgery, Brain, Microelectrode, Precision, Mount Sinai Health System, Medical device

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.

Key Points: 
  • NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the world record for number of electrodes placed on and recording cortical data from a human brain.
  • The previous published record for number of electrodes recording from a human brain was 2,048, demonstrated by Tan et al in 2023 .
  • The device’s modular design allows for multiple arrays to be placed alongside one another, mapping larger regions of brain activity in high resolution.
  • All Precision Neuroscience research conducted at Mount Sinai is conducted by independent investigators without financial ties to the company.

Vive Crop Protection Secures Series C Extension Funding to Accelerate Agricultural Innovation

Retrieved on: 
Giovedì, Maggio 23, 2024
Crop protection, Farmer, Partner, Vive Crop Protection, Growth, Face, Precision, Series

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Vive Crop Protection, the leading innovator in evolving crop inputs through its cutting-edge Precision Chemistry™ platform, proudly announces the successful closure of its Series C extension funding round.

Key Points: 
  • TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Vive Crop Protection, the leading innovator in evolving crop inputs through its cutting-edge Precision Chemistry™ platform, proudly announces the successful closure of its Series C extension funding round.
  • The Series C extension injects substantial capital into Vive to further advance its ground-breaking technologies and drive demand into new markets.
  • This strategic investment underscores the growing demand for sustainable agricultural solutions and positions Vive for continued growth and impact in the industry.
  • "We are thrilled to receive strong support from our existing shareholders as we advance our mission of transforming agriculture through innovation," says Darren Anderson, CEO of Vive Crop Protection.

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Venerdì, Maggio 17, 2024
Research, Technology, Genetics, Health Technology, Software, Other Health, Biotechnology, Health, Science, Other Science, Employment, Precision, Common stock, Precision BioSciences, Gene editing, Compensated emancipation

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).
  • Each award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employees to commence service with Precision.
  • The stock option has a per share exercise price equal to the fair market value of Precision’s Common Stock on May 13, 2024, which was equal to $11.50.
  • Each employee’s RSUs vest (subject to continued service to Precision through the applicable vesting dates) in substantially equal annual installments on each of the first three anniversaries of the date of the commencement of such individual’s employment.

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Lunedì, Maggio 13, 2024
Science, Biometrics, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Janus, CTA, Novartis, Autoimmune disease, Sickle cell disease, IND, Hemoglobinopathy, OTC, Primate, Neuron, Fast Track, Vivo, RNA, CRISPR, Therapy, TRAC, Gene editing, Cell, Patent, NHP, Hepatitis B virus, HBV, Mitochondrion, ATM, Administration, CccDNA, PMM, Infant, Economics, Precision BioSciences, Rachel Haurwitz, Food, AAV, Duchenne muscular dystrophy, Cancer, Mitochondrial disease, Nature Metabolism, Precision, Patient, DNA, University, Gene, Cash, Development, Central nervous system, Pharmaceutical industry

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • PBGENE-HBV is advancing through final toxicology studies and Precision expects to submit an IND and/or CTA for this program in 2024.
  • Cash and Cash Equivalents: As of March 31, 2024, Precision had approximately $137.8 million in cash and cash equivalents.
  • Shares: Basic weighted-average common shares outstanding for the first quarter of 2024 were 5,060,978 compared to 3,709,894 for the same period in 2023.

Precision for Medicine Opens Expanded State-of-the-Art Biomarker Research and Companion Diagnostic Laboratory in Frederick, Maryland

Retrieved on: 
Martedì, Maggio 14, 2024
Medicine, Patient, Research, Doctor of Philosophy, Growth, Precision

BETHESDA, Md., May 14, 2024 /PRNewswire/ -- Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, today announced the completion of a major expansion to its laboratory campus in Frederick, Maryland. Now with 125,000 square feet of state-of-the-art capabilities the facility offers significantly increased capacity and scale across both biorepository and laboratory services, with particular focus on cell and gene therapy, oncology and viral research.

Key Points: 
  • Now with 125,000 square feet of state-of-the-art capabilities the facility offers significantly increased capacity and scale across both biorepository and laboratory services, with particular focus on cell and gene therapy, oncology and viral research.
  • With this expansion, the Frederick laboratory campus serves as a center of excellence for Precision for Medicine's gene therapy companion diagnostic manufacturing, advanced immunological monitoring research, large molecule BioAnalytical testing services, complex sample kitting manufacturing and global logistics.
  • "We see this as a benefit for our clients and, ultimately, for the patients who will be helped by these treatment advances."
  • "Our Frederick campus positions us to capitalize on the growth we are seeing in the life sciences industry," said Deborah Phippard, PhD, Chief Scientific Officer of Precision for Medicine.

Precision Support Services Strengthens SmartSky® Dealer Network Installs SmartSky LITE™ ATG on PC-12

Retrieved on: 
Martedì, Maggio 14, 2024
Partnership, Bell, Pilatus, Aircraft, ATG, MRO, Airbus, Precision, Maintenance (technical)

RESEARCH TRIANGLE, N.C., May 14, 2024 /PRNewswire/ -- SmartSky, provider of the most advanced inflight air-to-ground (ATG) connectivity for business aviation, today announced Precision Support Services has joined the SmartSky dealer network as a sales and installation partner.

Key Points: 
  • RESEARCH TRIANGLE, N.C., May 14, 2024 /PRNewswire/ -- SmartSky, provider of the most advanced inflight air-to-ground (ATG) connectivity for business aviation, today announced Precision Support Services has joined the SmartSky dealer network as a sales and installation partner.
  • The Oregon-based aviation company offers full Maintenance, Repair, and Overhaul (MRO) services and has already completed an installation of SmartSky LITE on a Pilatus PC-12.
  • "Precision's partnership with SmartSky is important because it adds capabilities to a proven inflight connectivity product already making waves in the marketplace.
  • "Precision's aircraft maintenance expertise strengthens SmartSky's presence in the region," said Aria Bahawdory, Director of MRO Account Management for SmartSky.

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Martedì, Maggio 7, 2024
Research, Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Health, Other Science, Science, CTA, Fast Track, Safety, Pharmacokinetics, Food, European Commission, OTC, Gene editing, Communication, Collection, IND, Therapy, Precision BioSciences, Patient, Civil service commission, Standard of care, Precision, Vaccine

ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.

Key Points: 
  • ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
  • The Fast Track designation is designed to facilitate the development and expedite the review of therapeutics to treat serious conditions that fill an unmet medical need.
  • Provided relevant criteria are met, programs with Fast Track designation are eligible for accelerated approval and priority review as well.
  • “Congratulations to iECURE for this significant regulatory designation and for what it can potentially mean to patients with neonatal onset OTC deficiency.

Precision Aerospace Holdings, LLC Acquires Owens Machine and Tool Company

Retrieved on: 
Martedì, Maggio 7, 2024
Other Defense, Machinery, Contracts, Machine Tools, Metalworking & Metallurgy, Transportation, Defense, Travel, Other Manufacturing, Engineering, Air, Transport, Aerospace, Manufacturing, CNC, AS9100, Partnership, CIC, Titanium, Acquisition, ITAR, Precision, Growth

Dallas-based Precision Aerospace Holdings LLC (Precision), a leading manufacturer of precision machined aerospace and defense components, has acquired Owens Machine and Tool Company (Owens).

Key Points: 
  • Dallas-based Precision Aerospace Holdings LLC (Precision), a leading manufacturer of precision machined aerospace and defense components, has acquired Owens Machine and Tool Company (Owens).
  • Owens produces complex, multifaceted parts, tooling and prototypes utilizing multi-axis machine tools and best-in-class cutting tools.
  • It was established in 1986 to develop and sell complex machine components, primarily to the aerospace and defense industries.
  • “The Owens team has deep experience that expands our broad capabilities to provide world-class service to aerospace and defense industries.

Festool Releases Limited Editions That Take Portability and Precision to the Next Level

Retrieved on: 
Martedì, Maggio 7, 2024
KSC, TCL, Safety, CTC, Cordless, Yeti, Workflow, Portability, TSC, LED, Stiffness, Longevity, Precision

LEBANON, Ind., May 7, 2024 /PRNewswire/ -- Festool, a leading manufacturer of innovative, precision-engineered, and durable power tool solutions, today unveiled a range of limited-edition cordless combo kits and router solutions designed to meet the evolving needs of professionals while enhancing workshop and jobsite efficiency. Available beginning June 3, 2024, two limited-edition cordless combo kits, the limited-edition OF 1010 R REQ-F-Plus Router with Light Module, the Festool Level, and the limited-edition Summer Systainer are set to optimize performance for professionals no matter the specialty.

Key Points: 
  • Each kit is designed to kickstart or expand Festool cordless collections by providing convenience, performance, flexibility, and quality.
  • Precision Cutting: The TSC 55 K Cordless Track Saw offers unmatched power and accuracy that guarantees flawless cuts every time, plus a safety enhancing KickBackStop function.
  • Limited-Edition OF 1010 REQ-F-Plus + Light Module: Precision and Clarity For Every Job
    The OF 1010 REQ-F-Plus router, enhanced with an LED Light Module, offers unmatched precision and ease of use.
  • The Festool Level (577220) will be available at $65.00.

All Three Leading Independent Proxy Advisory Firms Recommend Norfolk Southern Shareholders Vote “FOR” Significant Boardroom Change on the BLUE Proxy Card

Retrieved on: 
Venerdì, Maggio 3, 2024
Professional Services, Finance, Trade, Egan-Jones Ratings Company, Norfolk Southern Railway, ISS, Safety, Annual general meeting, NSC, Blue, Thought, Precision, Glass, Management

Notably, all three proxy advisory firms also recommend voting AGAINST Norfolk Southern’s proposed executive compensation.

Key Points: 
  • Notably, all three proxy advisory firms also recommend voting AGAINST Norfolk Southern’s proposed executive compensation.
  • All three proxy advisory firms now support significant change at Norfolk Southern.
  • If shareholders support a majority change of the Board, they can ensure that operationally proficient management commences a network redesign and properly implements Precision Scheduled Railroading.
  • This three-year strategy, which differs greatly from Norfolk Southern’s resilience railroading model, has driven superior service, safety and long-term value at every other publicly-traded Class I rail.